AMAREX seems not to be the only incompetent screw
Post# of 147890
(Total Views: 640)
Posted On: 12/16/2021 5:22:36 AM
AMAREX seems not to be the only incompetent screw up CRO out there. I hope Dr. Kelly and Dr. Recknor take a steady good look on our new CROs.
Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem
This screw up cost the shareholder deeply. They went off a clip at 8USD to almost 1,3USD and now recovered to almost 3USD. Shareholder still lost more than 50% at the current SP.
It would be an unbelievable story if you did not follow the AMAREX story at Cytodyn before.
Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem
This screw up cost the shareholder deeply. They went off a clip at 8USD to almost 1,3USD and now recovered to almost 3USD. Shareholder still lost more than 50% at the current SP.
It would be an unbelievable story if you did not follow the AMAREX story at Cytodyn before.
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼